drugset / Trial / NCT05128383
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
Phase 2
Completed
20 enrolled
Beth Israel Deaconess Medical Center
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The study investigates the efficacy and safety of dupilumab in the treatment of keloids
Timeline
- Start
- 2023-01-13
- Primary completion
- 2025-05-19
- Completion
- 2025-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |